Search clinical trials for: 5 mg empagliflozin

Total 17198 results

Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Centre Hospitalier Universitaire Vaudois
University College, London; Great Ormond Street Hospital for Children NHS Foundation...

Not yet recruiting

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Heart Failure

Switzerland, United Kingdom
AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Assiut University

Not yet recruiting

SGLT2 Inhibitors and Perioperative Period

Perioperative Complication
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Beni-Suef University

Recruiting

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

PCO

Egypt
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
Sohag University

Not yet recruiting

The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus

Fatty Liver, Nonalcoholic
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
AstraZeneca

Not yet recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

United States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
October 6 University
University of Florida; Beni-Suef University; National Heart Institute, Egypt

Recruiting

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

Heart Failure | Genetic Polymorphisms

United States
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
University of Campinas, Brazil
AstraZeneca

Completed

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (ADDENDA)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery Diseases

Brazil
AstraZeneca

Not yet recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

United States, Canada, Finland, France, Germany, Italy, Spain, United Kingdom, Thailand, Vietnam, Korea, Republic of, Mexico, Peru, Philippines, Turkey, China, Taiwan, Austria, Slovakia, Chile, Argentina, Japan, Czechia, Greece, Hungary, ... and more
Beijing Anzhen Hospital

Recruiting

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Coronary Artery Disease | Diabete Mellitus

China
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
Clinical Research Centre, Malaysia
University of Malaya; Ministry of Health, Malaysia

Recruiting

The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD) (EpiCAD)

Coronary Artery Disease

Malaysia
AstraZeneca

Completed

Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.

Type 2 Diabetes Mellitus

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Kiyuk Chang
Seoul St. Mary's Hospital; Pusan National University Hospital; Korea University... and other collaborators

Recruiting

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients With Acute Myocardial Infarction, a Prospective, Multi-center Registry Study (RECORD-AMI)

Myocardial Infarction | Diabetes Mellitus, Type 2

Korea, Republic of
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Centro Universitario de Ciencias de la Salud, Mexico

Unknown

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes

Hyperglycemia | Diabetes Mellitus, Type 2

United States, Brazil, Canada, Czech Republic, Egypt, France, Germany, Guatemala, Korea, Republic of, Lebanon, Malaysia, Mexico, Peru, Philippines, Russian Federation, Serbia, Spain, Taiwan, Thailand, Turkey, United Kingdom
Amsterdam UMC, location VUmc

Completed

SGLT2 Inhibition: Uric Acid Excretion Study (UREX)

Type 2 Diabetes

Netherlands
University Hospital Tuebingen

Terminated

Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment (DapaSaxaBBIT)

Type 2 Diabetes

Germany
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
University of Pisa

Unknown

SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. (UTI-flog)

Type 2 Diabetes | Urinary Tract Infections

Italy
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Tanta University

Active, not recruiting

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Diabetic Neuropathy Peripheral

Egypt
The University of Hong Kong
Research Grant Council

Recruiting

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B

Cirrhosis | NAFLD | Chronic Hepatitis b | Fibrosis, Liver | Empagliflozin | SGLT2 Inhibitors

Hong Kong
The University of Hong Kong
Food and Health Bureau, Hong Kong

Completed

Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Non-alcoholic Fatty Liver Disease

Hong Kong
University of Sao Paulo General Hospital

Recruiting

iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...

Recruiting

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Type2 Diabetes | Heart Failure With Preserved Ejection Fraction

United States
Pfizer

Completed

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects

Healthy

United States

Search clinical trials for: 5 mg empagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations